<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45139">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01795326</url>
  </required_header>
  <id_info>
    <org_study_id>D1443C00127</org_study_id>
    <nct_id>NCT01795326</nct_id>
  </id_info>
  <brief_title>Physician Survey on Monitoring of Patients Treated With Quetiapine</brief_title>
  <official_title>Assessment of Physician Behavior Regarding Metabolic Monitoring of Patients Treated With SEROQUEL® (Quetiapine Fumarate) Tablets and SEROQUEL® (Quetiapine Fumarate) Extended Release Tablets in Selected Countries in the EU</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>Netherlands: Medicines Evaluation Board (MEB)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A physician survey to document receipt of metabolic educational materials and assess
      behavior of physicians in following messages communicated through the educational materials
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assessment of physician behavior regarding metabolic monitoring of patients treated with
      SEROQUEL®   (quetiapine fumarate) Tablets and SEROQUEL®  (quetiapine fumarate) Extended
      Release Tablets in selected countries in the EU
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Determination via survey whether physicians or someone in their practice perform monitoring of patients treated with Seroquel or Seroquel XR for metabolic issues related to treatment; refer their patients to another physician for monitoring.</measure>
    <time_frame>Over 6- 8 weeks.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination via survey whether physicians monitor tests for hyperlipidemia in patients who are taking Seroquel or Seroquel XR.</measure>
    <time_frame>Over 6- 8 weeks.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination via survey whether physicians monitor for signs and symptoms of  hyperglycemia in patients who are taking Seroquel or Seroquel XR.</measure>
    <time_frame>Over 6- 8 weeks.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination via survey whether physicians monitor blood glucose in patients with diabetes or monitor patients with risk factors for diabetes for worsening of glycemic control if they are taking Seroquel or Seroquel XR.</measure>
    <time_frame>Over 6- 8 weeks.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination via survey whether physicians monitor weight at initiation of treatment with Seroquel or Seoquel XR and on a regular basis after initiating treatment.</measure>
    <time_frame>Over 6- 8 weeks.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination via survey whether physicians counsel patients taking with Seroquel or Seroquel XR on healthy eating, exercise, and healthy lifestyle improvements.</measure>
    <time_frame>Over 6- 8 weeks.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination via survey whether physicians received educational information relevant to the issues in the survey from AstraZeneca.</measure>
    <time_frame>Over 6- 8 weeks.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination via survey whether physicians read the educational information.</measure>
    <time_frame>Over 6- 8 weeks.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Actual">800</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Bipolar Disorder</condition>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Germany</arm_group_label>
    <description>A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>United Kingdom</arm_group_label>
    <description>A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spain</arm_group_label>
    <description>A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hungary</arm_group_label>
    <description>A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Netherlands</arm_group_label>
    <description>A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sweden</arm_group_label>
    <description>A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Romania</arm_group_label>
    <description>A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Italy</arm_group_label>
    <description>A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        A sample of physicians who were targeted to receive the metabolic educational materials
        and either currently prescribe or have the potential to prescribe SEROQUEL®  or SEROQUEL®
        XR.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Physicians targeted to receive the metabolic educational materials and either
             currently prescribe or have the potential to prescribe SEROQUEL®  or SEROQUEL®  XR.

        Exclusion Criteria:

          -  Physicians who have participated in a survey involving SEROQUEL® / SEROQUEL®  XR in
             the past six months are not eligible to participate in this survey.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert S Brody, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZ</affiliation>
  </overall_official>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 27, 2014</lastchanged_date>
  <firstreceived_date>February 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Effectiveness of risk minimization</keyword>
  <keyword>Metabolic monitoring</keyword>
  <keyword>Seroquel®</keyword>
  <keyword>Seroquel® XR/quetiapine fumarate</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Quetiapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
